AUTISM SPECTRUM DISORDER THERAPEUTICS MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: BYR-170441 | Healthcare
Historical data: 2018 - 2023
Forecast period: 2024 - 2031
Quantitative units: Revenue in USD million and CAGR from 2024 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Autism Spectrum Disorder Therapeutics Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL AUTISM SPECTRUM DISORDER THERAPEUTICS MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL AUTISM SPECTRUM DISORDER THERAPEUTICS MARKET
7.1 GLOBAL AUTISM SPECTRUM DISORDER THERAPEUTICS MARKET SIZE AND SHARE (2018-2031) (USD MILLION)
8.1 GLOBAL AUTISM SPECTRUM DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
8.2 GLOBAL AUTISM SPECTRUM DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
9.1 GLOBAL AUTISM SPECTRUM DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
9.2 GLOBAL AUTISM SPECTRUM DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
10.1 GLOBAL AUTISM SPECTRUM DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)
10.2 GLOBAL AUTISM SPECTRUM DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)
11.1 NORTH AMERICA AUTISM SPECTRUM DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
11.2 NORTH AMERICA AUTISM SPECTRUM DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
11.3 NORTH AMERICA AUTISM SPECTRUM DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
11.4 NORTH AMERICA AUTISM SPECTRUM DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
11.5 NORTH AMERICA AUTISM SPECTRUM DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
11.6 NORTH AMERICA AUTISM SPECTRUM DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
12.1 EUROPE AUTISM SPECTRUM DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
12.2 EUROPE AUTISM SPECTRUM DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
12.3 EUROPE AUTISM SPECTRUM DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
12.4 EUROPE AUTISM SPECTRUM DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
12.5 EUROPE AUTISM SPECTRUM DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
12.6 EUROPE AUTISM SPECTRUM DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
13.1 ASIA PACIFIC AUTISM SPECTRUM DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
13.2 ASIA PACIFIC AUTISM SPECTRUM DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
13.3 ASIA PACIFIC AUTISM SPECTRUM DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
13.4 ASIA PACIFIC AUTISM SPECTRUM DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
13.5 ASIA PACIFIC AUTISM SPECTRUM DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
13.6 ASIA PACIFIC AUTISM SPECTRUM DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
14.1 LATIN AMERICA AUTISM SPECTRUM DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>
14.2 LATIN AMERICA AUTISM SPECTRUM DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
14.3 LATIN AMERICA AUTISM SPECTRUM DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
14.4 LATIN AMERICA AUTISM SPECTRUM DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
14.5 LATIN AMERICA AUTISM SPECTRUM DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
14.6 LATIN AMERICA AUTISM SPECTRUM DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA AUTISM SPECTRUM DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA AUTISM SPECTRUM DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA AUTISM SPECTRUM DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA AUTISM SPECTRUM DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA AUTISM SPECTRUM DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA AUTISM SPECTRUM DISORDER THERAPEUTICS MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>
16.1 F. Hoffmann-La Roche AG
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 Neurim Pharmaceuticals, Inc.
16.3 Yamo Pharmaceuticals LLC
16.4 Servier Laboratories Ltd.
16.5 Otsuka Holdings Co. Ltd.
16.6 Curemark LLC
16.7 Oryzon Genomics S.A.
16.8 GW Pharmaceuticals Plc.
16.9 Teva Pharmaceutical Industries Ltd.
16.10 Zynerba Pharmaceuticals Inc.
16.11 Stalicla SA.
16.12 Novartis AG
16.13 Pfizer, Inc.
16.14 Bristol Myers Squibb
16.15 Allergan
16.16 Q BioMed Inc
16.17 Hopebridge, LLC.
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
By Drug TypeAripiprazole
Risperidone
Melatonin
CM-AT
Bumetanide
Balovaptan
By Age Group  
Child
Adult
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Companies
F. Hoffmann-La Roche AG
Neurim Pharmaceuticals, Inc.
Yamo Pharmaceuticals LLC
Servier Laboratories Ltd.
Otsuka Holdings Co. Ltd.
Curemark LLC
Oryzon Genomics S.A.
GW Pharmaceuticals Plc.
Teva Pharmaceutical Industries Ltd.
Zynerba Pharmaceuticals Inc.
Stalicla SA.
Novartis AG
Pfizer, Inc.
Bristol Myers Squibb
Allergan
Q BioMed Inc
Hopebridge, LLC.
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.